Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD-Reference-Cited by-同舟云学术

Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD

Published:2022-02 Issue:2 Volume:7 Page:200-209
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Walsh Michael^ORCID,Bethune Claudette,Smyth Andrew,Tyrwhitt Jessica,Jung Shiangtung W.,Yu Rosie Z.,Wang Yanfeng,Geary Richard S.,Weitz Jeffrey,Bhanot Sanjay

Publisher

Elsevier BV

Subject

Nephrology

Reference25 articles.

1. The atrial fibrillation conundrum in dialysis patients;De Vriese;Am Heart J,2016

2. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events;Preis;Blood,2017

3. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of thromboembolism Etiology;Cushman;Blood,2009

4. High levels of coagulation factor XI as a risk factor for venous thrombosis;Meijers;N Engl J Med,2000

5. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency;Salomon;Blood,2008

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Catheter‐related deep vein thrombosis: Where are we at and where are we going? Updates and ongoing unmet clinical needs;European Journal of Clinical Investigation;2024-09-12

2. Antithrombotic Strategies for Patients With Peripheral Artery Disease;Journal of the American College of Cardiology;2024-09

3. Anticoagulant therapy in renal insufficiency theme: Anticoagulation in complex situations;Thrombosis Research;2024-09

4. A Case Report of a Hemodialysis Patient With Coagulation Factor XI and Factor XII Deficiencies;Seminars in Dialysis;2024-08-18

5. Milvexian: An Oral, Bioavailable Factor XIa Inhibitor;Cardiology and Therapy;2024-08-17